-$0.14 Earnings Per Share Expected for Mediwound Ltd (NASDAQ:MDWD) This Quarter

Share on StockTwits

Brokerages expect that Mediwound Ltd (NASDAQ:MDWD) will post earnings per share (EPS) of ($0.14) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Mediwound’s earnings. The lowest EPS estimate is ($0.19) and the highest is ($0.11). Mediwound reported earnings per share of ($0.11) in the same quarter last year, which indicates a negative year-over-year growth rate of 27.3%. The company is expected to issue its next earnings report on Tuesday, November 12th.

On average, analysts expect that Mediwound will report full-year earnings of ($0.33) per share for the current fiscal year, with EPS estimates ranging from ($0.66) to $0.08. For the next fiscal year, analysts forecast that the firm will report earnings of ($0.54) per share, with EPS estimates ranging from ($0.62) to ($0.45). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Mediwound.

Mediwound (NASDAQ:MDWD) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03. Mediwound had a net margin of 70.54% and a negative return on equity of 156.56%. The firm had revenue of $20.75 million during the quarter, compared to analyst estimates of $7.03 million.

MDWD has been the subject of a number of research reports. HC Wainwright initiated coverage on shares of Mediwound in a research note on Monday, August 5th. They issued a “buy” rating and a $5.50 price objective for the company. ValuEngine raised shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Friday, July 12th. Finally, Oppenheimer lowered their price objective on shares of Mediwound from $15.00 to $7.00 and set an “outperform” rating for the company in a research note on Wednesday, August 14th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Mediwound currently has a consensus rating of “Buy” and a consensus target price of $7.25.

NASDAQ:MDWD opened at $3.01 on Friday. Mediwound has a 1-year low of $2.55 and a 1-year high of $6.75. The company has a 50-day moving average of $3.16 and a 200 day moving average of $4.23. The company has a quick ratio of 3.99, a current ratio of 4.13 and a debt-to-equity ratio of 0.11.

A number of large investors have recently added to or reduced their stakes in MDWD. ARK Investment Management LLC purchased a new stake in Mediwound in the second quarter worth about $325,000. Menta Capital LLC lifted its position in shares of Mediwound by 200.2% during the first quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 29,686 shares during the last quarter. Delek Group Ltd. purchased a new stake in shares of Mediwound during the first quarter valued at about $141,000. Marshall Wace LLP purchased a new stake in shares of Mediwound during the first quarter valued at about $93,000. Finally, Millennium Management LLC lifted its position in shares of Mediwound by 33.2% during the fourth quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 17,048 shares during the last quarter. 30.78% of the stock is owned by institutional investors.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Article: How do candlesticks reflect price movement?

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Delta Apparel, Inc.  Sees Significant Decrease in Short Interest
Delta Apparel, Inc. Sees Significant Decrease in Short Interest
Intelligent Systems Co.  Sees Large Growth in Short Interest
Intelligent Systems Co. Sees Large Growth in Short Interest
Vietnam Enterprise Investments  Stock Price Up 0.4%
Vietnam Enterprise Investments Stock Price Up 0.4%
Chesapeake Gold  Stock Price Up 1.7%
Chesapeake Gold Stock Price Up 1.7%
Creightons  Stock Price Up 1.4%
Creightons Stock Price Up 1.4%
Costar Technologies  Trading Down 5%
Costar Technologies Trading Down 5%


© 2006-2019 Ticker Report